Results of a phase Ib trial demonstrated the safety and tolerability of danvatirsen in DLBCL as well as a promising efficacy of STAT3 ASO with two complete responses and two partial responses in patients with DLBCL (n = 30) (NCT01563302) [116]. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.